The Effect of a Home-Based Exercise Intervention on Metabolic Syndrome and Breast Cancer Risk in African-American Women

TON - March 2017, Vol 10, No 2 - Breast Cancer
Meg Barbor, MPH

Cape Town, South Africa—Breast cancer rates are increasing worldwide, paralleling increases in type 2 diabetes, obesity, and metabolic syndrome (MetS). According to Lucile L. Adams-Campbell, PhD, epidemiologist, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, mortality from these and other diseases is still higher among African-American populations than white populations, regardless of incidence rates. “So that’s where we have to intervene,” she said at the American Association for Cancer Research International Conference on New Frontiers in Cancer Research.

MetS represents a cluster of components associated with an increased risk for cardiovascular disease and includes several risk factors for breast cancer, such as central obesity, hypertension, hyperglycemia, and low high-density lipoprotein cholesterol. Weight gain and obesity are associated with an increased risk for postmenopausal breast cancer, whereas a higher body mass index is associated with a lower risk for premenopausal breast cancer.

“The majority of black people in the US are obese, and something has to be done about that,” said Dr Adams-Campbell. Although the overall incidence of breast cancer in the United States is slightly higher among white women than among black women, the numbers are beginning to equalize, she noted. And the increase in obesity among black women could be a major contributor to this trend.

Study Design

Dr Adams-Campbell and her co-investigators hypothesized that lifestyle interventions may improve the MetS profile and reduce breast cancer risk among black women with MetS who are at an increased risk for breast cancer. This risk measurement was based on the Contraceptive and Reproductive Experiences model, which allows researchers to estimate an African-American woman’s risk of developing invasive breast cancer.

The randomized, controlled FIERCE (Focused Intervention on Exercise to Reduce Cancer) trial compared the impact of a supervised facility-based exercise program and a home-based exercise intervention on obesity, MetS components, and known breast cancer biomarkers in sedentary, postmenopausal, metabolically unhealthy African-American women at increased risk for breast cancer. More than 1500 black women aged 45 to 65 years were screened, and a total of 213 participants were randomized to the trial over a 6-month period.

Seventy-three women were enrolled in the supervised facility-based exercise arm; they reported to a facility 3 times per week for 6 months, for a total of 75 to 150 minutes per week of exercise. Participants in this group kept an exercise diary and made no dietary changes.

A total of 69 women in the home-based exercise group exercised 30 to 45 minutes per day, 4 days per week, over the 6-month study period. They were encouraged to take 10,000 steps a day, and participants received weekly encouraging text messages, or “goal motivators.” Members of this cohort also kept an exercise diary and made no dietary changes.

The control arm was comprised of 71 women. Members of this group also received weekly text messages but were told to keep up their current daily activities and exercise habits, with no changes in diet.

“We only wanted to focus on the impact of exercise. And it’s important to note that smoking is not a big issue in black women, as we’ve seen in numerous studies,” Dr Adams-Campbell said.

Home-Based Intervention Shown More Effective

The data revealed that the home-based intervention arm had more favorable changes in metabolic components compared with the supervised and control groups, Dr Adams-Campbell reported.

“What’s interesting and bothersome at the same time is that the home-based group had a mean weight loss of 12 pounds at 6-month follow-up, but the supervised and control groups gained weight,” she said.

The home-based group also experienced more positive changes in diastolic blood pressure than the supervised group, and it was the only arm to experience a drop in serum triglycerides, for an approximate 20% overall change in MetS components from baseline. Both the home-based and the supervised arms improved in MetS overall, but supervised participants had lower study adherence compared with the home-based participants.

“In this trial, the home-based intervention group, overall, was more effective in improving anthropometric and metabolic syndrome components linked to breast cancer. Obesity is a major contributor to many diseases and cancers, not just breast cancer, so if we can make an impact on obesity, I think that will be very important,” said Dr Adams-Campbell.

She said these findings suggest broad public health utility in addressing lifestyle interventions among black women.

Related Items
Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer
Rebecca Bailey
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in Breast Cancer, Immunotherapy
Strategies to Address the Long-Term Financial Burden of Cancer in Survivors
Meg Barbor, MPH
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in Survivorship, Financial/Insurance Information
Fear of Recurrence in Cancer Survivors Different from Depression or Distress
Meg Barbor, MPH
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in Survivorship, Financial/Insurance Information
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
TON Web Exclusives published on April 7, 2018 in Breast Cancer, Online Only, In the News
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, AONN+ News
Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Breast Cancer, Drug Updates & News, ESMO
The Challenges of Oral Cancer Drugs Use and Side-Effects Management
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Side-Effects Management, Drug Updates & News, ESMO
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Last modified: March 7, 2017